Liminatus Pharma, Inc. has appointed Eric Sunghee Kang as its Chief Corporate Strategist, effective November 16, 2026. This strategic appointment is aimed at strengthening the company’s corporate finance and capital markets strategies, particularly in managing financing transactions and developing new business initiatives.

Mr. Kang, age 43, brings a wealth of experience to the role. He has been the Chief Executive Officer of Quantinum Investment since 2022, focusing on cross-border capital markets transactions. His previous roles include Head of Strategy and Finance at a Nasdaq-listed company and Chief Executive Officer of a Korean asset management firm. His background also includes significant experience at global financial institutions, such as Morgan Stanley and HSBC.

According to the filing, Liminatus Pharma believes that Mr. Kang’s extensive experience in both U.S. and Asian capital markets will be invaluable as the company seeks additional financing and new business initiatives to enhance stockholder value. Notably, Mr. Kang will not receive any compensation for his services in this role.

This appointment comes at a time when the biological products industry is increasingly focused on strategic leadership to navigate complex financing environments. Liminatus Pharma, which operates under the SIC code 2836, is positioned to leverage Mr. Kang's expertise to enhance its market presence and financial strategies.

As the company moves forward, it will be interesting to see how this strategic addition impacts its operations and competitive positioning in the biological products sector.

The filing does not specify what happens next for Liminatus Pharma following this appointment.